OBJECTIVE: To evaluate whether the amyloid-binding agent carbon 11-labeled Pittsburgh Compound B ((11)C-PiB) could differentiate Alzheimer disease (AD) from human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) in middle-aged HIV-positive participants. DESIGN: (11)C-PiB scanning, clinical assessment, and cerebrospinal fluid (CSF) analysis were performed. Both χ(2) and t tests assessed differences in clinical and demographic variables between HIV-positive participants and community-living individuals observed at the Knight Alzheimer's Disease Research Center (ADRC). Analysis of variance assessed for regional differences in amyloid-β protein 1-42 (Aβ42) using (11)C-PiB. SETTING: An ADRC and HIV clinic. PARTICIPANTS: Sixteen HIV-positive participants (11 cognitively normal and 5 with HAND) and 19 ADRC participants (8 cognitively normal and 11 with symptomatic AD). MAIN OUTCOME MEASURES: Mean and regional (11)C-PiB binding potentials. RESULTS: Participants with symptomatic AD were older (P < .001), had lower CSF Aβ42 levels (P < .001), and had higher CSF tau levels (P < .001) than other groups. Regardless of degree of impairment, HIV-positive participants did not have increased (11)C-PiB levels. Mean and regional binding potentials were elevated for symptomatic AD participants (P < .001). CONCLUSIONS: Middle-aged HIV-positive participants, even with HAND, do not exhibit increased (11)C-PiB levels, whereas symptomatic AD individuals have increased fibrillar Aβ42 deposition in cortical and subcortical regions. Observed dissimilarities between HAND and AD may reflect differences in Aβ42 metabolism. (11)C-PiB may provide a diagnostic biomarker for distinguishing symptomatic AD from HAND in middle-aged HIV-positive participants. Future cross-sectional and longitudinal studies are required to assess the utility of (11)C-PiB in older individuals with HAND.
OBJECTIVE: To evaluate whether the amyloid-binding agent carbon 11-labeled Pittsburgh Compound B ((11)C-PiB) could differentiate Alzheimer disease (AD) from humanimmunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) in middle-aged HIV-positive participants. DESIGN: (11)C-PiB scanning, clinical assessment, and cerebrospinal fluid (CSF) analysis were performed. Both χ(2) and t tests assessed differences in clinical and demographic variables between HIV-positive participants and community-living individuals observed at the Knight Alzheimer's Disease Research Center (ADRC). Analysis of variance assessed for regional differences in amyloid-β protein 1-42 (Aβ42) using (11)C-PiB. SETTING: An ADRC and HIV clinic. PARTICIPANTS: Sixteen HIV-positive participants (11 cognitively normal and 5 with HAND) and 19 ADRC participants (8 cognitively normal and 11 with symptomatic AD). MAIN OUTCOME MEASURES: Mean and regional (11)C-PiB binding potentials. RESULTS:Participants with symptomatic AD were older (P < .001), had lower CSF Aβ42 levels (P < .001), and had higher CSF tau levels (P < .001) than other groups. Regardless of degree of impairment, HIV-positive participants did not have increased (11)C-PiB levels. Mean and regional binding potentials were elevated for symptomatic ADparticipants (P < .001). CONCLUSIONS: Middle-aged HIV-positive participants, even with HAND, do not exhibit increased (11)C-PiB levels, whereas symptomatic AD individuals have increased fibrillar Aβ42 deposition in cortical and subcortical regions. Observed dissimilarities between HAND and AD may reflect differences in Aβ42 metabolism. (11)C-PiB may provide a diagnostic biomarker for distinguishing symptomatic AD from HAND in middle-aged HIV-positive participants. Future cross-sectional and longitudinal studies are required to assess the utility of (11)C-PiB in older individuals with HAND.
Authors: Rebecca Craig-Schapiro; Richard J Perrin; Catherine M Roe; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Mark A Mintun; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Gina D'Angelo; James P Malone; R Reid Townsend; John C Morris; Anne M Fagan; David M Holtzman Journal: Biol Psychiatry Date: 2010-11-15 Impact factor: 13.382
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: C A Wiley; C L Achim; C Christopherson; Y Kidane; S Kwok; E Masliah; J Mellors; L Radhakrishnan; G Wang; V Soontornniyomkij Journal: AIDS Date: 1999-10-22 Impact factor: 4.177
Authors: Douglas A Green; Eliezer Masliah; Harry V Vinters; Pouneh Beizai; David J Moore; Cristian L Achim Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Nelleke Tolboom; Wiesje M van der Flier; Maqsood Yaqub; Ronald Boellaard; Nicolaas A Verwey; Marinus A Blankenstein; Albert D Windhorst; Philip Scheltens; Adriaan A Lammertsma; Bart N M van Berckel Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: Iain C Anthony; Stephen N Ramage; Frances W Carnie; Peter Simmonds; Jeanne E Bell Journal: Acta Neuropathol Date: 2006-05-09 Impact factor: 17.088
Authors: Mahfuz B Khan; Michelle J Lang; Ming-Bo Huang; Andrea Raymond; Vincent C Bond; Bruce Shiramizu; Michael D Powell Journal: J Neurovirol Date: 2015-09-25 Impact factor: 2.643